

FCDS CASEFINDING LIST FOR REPORTABLE TUMORS

REVISED SEPTEMBER 2009- EFFECTIVE WITH 2009 CASES

(REVISIONS ARE IN BOLD)

The following ICD-9-CM list is to be used to identify potentially reportable tumors. Some ICD-9-CM codes contain conditions that are not considered reportable. These records will need to be reviewed and assessed individually to verify whether or not they are reportable to FCDS. Casefinding must include both primary diagnoses and any subsequent or secondary diagnoses.

- * 042 AIDS (review cases for AIDS-related malignancies)
- * 140.0-208.9 Malignant neoplasms (excluding skin 173.0-173.9 with morphology codes 8000–8110)
- * 209.0-209.2 Malignant carcinoid tumors of the small and large intestines, rectum, and of other and unspecified sites
- * 209.30 Malignant poorly differentiated neuroendocrine tumors, any site
- * 225.0-225.9 Benign neoplasm of brain and spinal cord neoplasm
- * 227.3-227.4 Benign neoplasm of pituitary gland, pineal body, and other intracranial endocrine-related structures
- *227.9 Benign neoplasm; endocrine gland, site unspecified
- *228.02 Hemangioma; of intracranial structures
- * 230.0-234.9 Carcinoma in situ (excluding cervix – 233.1)
- + 235.0-238.9 Neoplasms of uncertain behavior
- * 236.0 Endometrial stroma, low grade (8931/3)
- * 237.5 Ependymoma (epithelial) (malignant) (9391/3)
- * 237.6 Papillary Meningioma (9538/3)
- * 238.4 Polycythemia vera (9950/3)
- * 238.6 Solitary plasmacytoma (9731/3), Extramedullary plasmacytoma (9734/3)
- * 238.71 Essential thrombocythemia (9962/3)
- * 238.72 Low grade myelodysplastic syndrome lesions (9980/3, 9982/3, 9985/3)
- * 238.73 High grade myelodysplastic syndrome lesions (9983/3)
- * 238.74 Myelodysplastic syndrome with 5q deletion (9986/3)
- * 238.75 Myelodysplastic syndrome, unspecified (9985/3)
- * 238.76 Myelofibrosis with myeloid metaplasia (9961/3)
- * 238.77 Post transplant lymphoproliferative disorder (9987/3)
- * 238.79 Other lymphatic and hematopoietic tissues (includes 9931/3, 9960/3, 9961/3)
- + 239.0-239.9 Neoplasms of unspecified behavior
- * 259.2 Carcinoid Syndrome
- * 273.2 Gamma heavy chain disease (9762/3); Franklin's disease (9762/3)
- * 273.3 Waldenstrom's macroglobulinemia (9761/3)
- * 288.3 Hypereosinophilic syndrome (9964/3)
- * 289.83 Myelofibrosis NOS (9961/3)
- *511.81 Malignant pleural effusion (code first malignant neoplasm if known)
- *789.51 Malignant ascites (code the first malignant neoplasm if known)
- *795.06 Papanicolaou smear of cervix with cytologic evidence of malignancy
- *795.16 Papanicolaou smear of vagina with cytologic evidence of malignancy
- *796.76 Papanicolaou smear of anus with cytologic evidence of malignancy**
- + V07.8 Other specified prophylactic measure
- + V10.0-V10.9 Personal history of malignancy (review these for recurrences, subsequent primaries, and/or subsequent treatment)
- * V58.0 Encounter for radiotherapy
- * V58.1 Encounter for chemotherapy and immunotherapy
- + V66.1 Convalescence following radiotherapy
- + V66.2 Convalescence following chemotherapy

- + V67.1 Radiation therapy follow-up
 - + V67.2 Chemotherapy follow-up
 - + V71.1 Observation for suspected malignant neoplasm
 - + V76.0-V76.9 Special screening for malignant neoplasm
- * = Required for review + = Optional for review**